Identification of PKC-isoform-specific biological actions using pharmacological approaches

Trends in Pharmacological Sciences

Volumn 21, Issue 5, 2000, Pages 181-187

  Way, Kerrie J ^a   Chou, Eva ^a   King, George L ^a  

^a JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 5 METHOXY 1H INDOL 3 YL] 3 [1H INDOL 3 YL]MALEIMIDE; 3 [1 (3 AMINOPROPYL) 3 INDOLYL] 4 (1 METHYL 3 INDOLYL) 1H PYRROLE 2,5 DIONE; 3 [8 [(DIMETHYLAMINO)METHYL] 6,7,8,9 TETRAHYDROPYRIDO[1,2 A]INDOL 10 YL] 4 (1 METHYL 1H INDOL 3 YL) 1H PYRROLE 2,5 DIONE; 7 HYDROXYSTAUROSPORINE; ANTISENSE OLIGONUCLEOTIDE; BISINDOLYLMALEIMIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; ISOENZYME; MALLOTOXIN; MIDOSTAURIN; PHOSPHATIDYLINOSITIDE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RESINIFERATOXIN; RO 317208; RO 318425; RO318220; RUBOXISTAURIN; STAUROSPORINE; THAPSIGARGIN; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; DRUG ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME LOCALIZATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; GENE EXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ENZYME ACTIVATORS; ENZYME INHIBITORS; HUMANS; ISOENZYMES; PROTEIN KINASE C; SUBSTRATE SPECIFICITY;

EID: 0034194092     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01468-1     Document Type: Review

References (50)

1. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 258:1992;607-614.
2. Hofmann J. The potential for isoenzyme-selective modulation of protein kinase C. FASEB J. 11:1997;649-669.
3. Kanashiro C.A., Khalil R.A. Signal transduction by protein kinase C in mammalian cells. Clin. Exp. Physiol. Pharmacol. 25:1998;974-985.
4. Liu W.S., Heckman C.A. The sevenfold way of PKC regulation. Cell Signal. 10:1998;529-542.
5. Mellor H., Parker P.J. The extended protein kinase C superfamily. Biochem J. 332:1998;281-292.
6. Newton A.C. Regulation of protein kinase C. Curr. Opin. Cell Biol. 9:1997;161-167.
7. Distanik M-H.et al. Localization of protein kinase C isozymes in cardiac myocytes. Exp. Cell Res. 210:1994;287-297.
8. Mochly-Rosen D., Gordon A.S. Anchoring proteins for protein kinase C: a means for isozyme selectivity. FASEB J. 12:1998;35-42.
9. Csukai M., Mochly-Rosen D. Pharmacologic modulation of protein kinase C isozymes: the role of RACKs and subcellular localization. Pharmacol. Res. 39:1999;253-259.
10. Nixon J.S. The biology of protein kinase C inhibitors. Parker P.J., Dekker L.V. Protein Kinase C. 1997;205-236 R.G. Landes Company.
11. Ishii H.et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science. 272:1996;728-731.
12. Wakasaki H.et al. Targeted overexpression of protein kinase C β2 isoform in myocardium causes cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A. 94:1997;9320-9325.
13. 2+-sensitive isoforms in the failing human heart. Circulation. 99:1999;384-391.
14. Dean N.M.et al. Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-α expression. Cancer Res. 56:1996;3499-3507.
15. Teicher B.A.et al. Enzymatic rationale and preclinical support for a potent protein kinase C β inhibitor in cancer therapy. Adv. Enzyme Regul. 39:1999;313-327.
16. Liu G.S.et al. Protein kinase C-ε is responsible for the protection of preconditioning in rabbit cardiomyocytes. J. Mol. Cell Cardiol. 31:1999;1937-1948.
17. Gschwendt M.et al. Rottlerin, a novel protein kinase inhibitor. Biochem. Biophys. Res. Commun. 199:1994;93-98.
18. Mizuno K.et al. UCN-01, an antitumor drug, is a selective inhibitor of the conventional PKC subfamily. FEBS Lett. 359:1995;259-261.
19. Seynaeve C.M.et al. Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. Mol. Pharmacol. 45:1994;1207-1214.
20. Marte B.M.et al. Protein kinase C and mammary cell differentiation: involvement of protein kinase C α in the induction of β-casein expression. Cell Growth Differ. 5:1994;239-247.
21. Martiny-Baron G.et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö6976. J. Biol. Chem. 268:1993;9194-9197.
22. Gschwendt M.et al. Inhibition of protein kinase C μ by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 392:1996;77-80.
23. Wilkinson S.E.et al. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem. J. 294:1993;335-337.
24. Jirousek M.R.et al. (S)-13[(Dimethylamino)methyl-10,11,14,15-tetrahydro-4,9:16.21-dimetheno-1H,13H- dibenzo[e, k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase Cβ J. Med. Chem. 39:1996;2664-2671.
25. Aiello L.P.et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes. 46:1997;1473-1480.
26. Nakamura J.et al. A protein kinase C-β-selective inhibitor ameliorate neural dysfunction in streptozotocin-induced diabetis rats. Diabetes. 48:1999;2090-2095.
27. Takeishi Y.et al. In vivo phosphorylation of cardiac troponin I by protein kinase Cβ2 decreases cardiomyocyte calcium responsiveness and contractility in transgenic mouse hearts. J. Clin. Invest. 102:1998;72-78.
28. Kowluru R.A.et al. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. V. Relationship between protein kinase C and ATPases. Diabetes. 47:1998;464-469.
29. Danis R.P.et al. Inhibition of intraocular neovascularization caused by retial ischemia in pigs by PKCβ inhibition with LY333531. Invest. Ophthalmol. Vis. Sci. 39:1998;171-179.
30. Ozaki H.et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am. J. Pathol. 156:2000;697-707.
31. Dean N.M.et al. Inhibition of protein kinase C-α expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J. Biol. Chem. 269:1994;16416-16424.
32. Geiger T.et al. Antitumor activity of a PKC-α antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anti-Cancer Drug Res. 13:1998;35-45.
33. Neumunaitis J.et al. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-α, in patients with advanced cancer. J. Clin. Oncol. 17:1999;3586-3595.
34. McKay R.A.et al. Characterization of a potent and specific class of antisense oligonuclotide inhibitor of human protein kinase C-α expression. J. Biol. Chem. 274:1999;1715-1722.
35. - generation but not degranulation or adherance in differentiated HL60 cells. J. Biol. Chem. 273:1998;27292-27299.
36. Liedtke C.M., Cole T.S. Antisense oligonucleotide to PKC-ε alters cAMP-dependent stimulation of CFTR in Calu-3 cells. Am. J. Physiol. 275:1998;C1357-C1364.
37. Sioud M., Sørensen D.R. A nuclease-resistant protein kinase Cα ribozyme blocks glioma cell growth. Nat. Biotechnol. 16:1998;556-561.
38. 1, γ, δ and ε by phorbol esters of different biological activities. FEBS Lett. 288:1991;5-9.
39. Llosas M.et al. Evidence for a role of conventional protein kinase-Cα in the control of homotypic contacts and cell scattering of HT-29 human intestinal cells. Biochem. J. 315:1996;1049-1054.
40. Kazanietz M.G.et al. Characterization of ligand and substrate specificity for the calcium-dependent and calcium-independent protein kinase C isozymes. Mol. Pharmacol. 44:1993;298-307.
41. Roivainen R., Messing R.O. The phorbol derivatives thymeleatoxin and 12-deoxyphorbol-13-O-phenylacetate-10-acetate cause translocation and down-regulation of multiple protein kinase C isozymes. FEBS Lett. 319:1993;31-34.
42. Geiges D.et al. Activation of protein kinase C subtypes α, γ, δ, ε, ζ, and η by tumor promoting and nontumor-promoting agents. Biochem. Pharmacol. 53:1997;865-875.
43. Watters D.J., Parsons P.G. Critical targets of protein kinase C in differentiation of tumour cells. Biochem. Pharmacol. 58:1999;383-388.
44. 3. J. Biol. Chem. 269:1994;32358-32367.
45. Ron D.et al. C2 region-derived peptides inhibit translocation and function of β protein kinase C in vivo. J. Biol. Chem. 270:1995;24180-24187.
46. Gray M.O.et al. A selective ε-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death. J. Biol. Chem. 272:1997;30945-30961.
47. Johnson J.A.et al. A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function. J. Biol. Chem. 271:1996;24962-24966.
48. Dorn G.W. IIet al. Sustained in vivo cardiac protection by a rationally designed peptide that causes ε protein kinase C translocation. Proc. Natl. Acad. Sci. U. S. A. 96:1999;12798-12803.
49. Ron D., Mochly-Rosen D. Agonists and antagonists of protein kinase C function, derived from its binding proteins. J. Biol. Chem. 269:1994;21395-21398.
50. Ron D., Mochly-Rosen D. An autoregulatory region in protein kinase C: the pseudoanchoring site. Proc. Natl. Acad. Sci. U. S. A. 92:1995;492-496.